Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 2/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642397 | 1.00 | PYGB (0.51) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL23867560 | 1.00 | PYGB (0.51) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL28453329 | 0.84 | PYGB (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL28463195 | 0.84 | PYGB (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL29217350 | 0.84 | PYGB (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL28902343 | 0.84 | PYGB (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL7211096 | 0.81 | PYGB (0.53) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL17523750 | 0.81 | SLC28A3 (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL22047951 | 0.81 | SLC28A3 (0.50) | PYGBL3MBTL1LGALS8MAPTGAA | |
| SCHEMBL22026379 | 0.81 | SLC28A3 (0.50) | PYGBL3MBTL1LGALS8MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090041740-A1 | CANCER TREATMENT BY METABOLIC MODULATIONS | ENGENE, INC. (CA) | 2009-02-12 | — | — | US | disclosed |
| US-20050202559-A1 | Cancer treatment by metabolic modulations | HERCULES CAPITAL, INC. | 2005-09-15 | — | — | US | disclosed |
| EP-1556088-A2 | COMPOSITIONS FOR CANCER TREATMENT | Engene, Inc. (CA) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004039412-A2 | COMPOSITIONS FOR CANCER TREATMENT | ENGENE, INC. (CA) | 2004-05-13 | — | — | WO | disclosed |